Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Kuo-Tung Hung,1 Shih-Cheng Yang,1 Cheng-Kun Wu,1,2 Hsing-Ming Wang,1 Chih-Chien Yao,1 Chih-Ming Liang,1,2 Wei-Chen Tai,1,2 Keng-Liang Wu,1,2 Yuan-Hung Kuo,1,2 Chen-Hsiang Lee,2,3 Seng-Kee Chuah1,2 1Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kao...

Full description

Bibliographic Details
Main Authors: Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK
Format: Article
Language:English
Published: Dove Medical Press 2021-03-01
Series:Infection and Drug Resistance
Subjects:
helicobacter pylori
esomeprazole
lansoprazole
concomitant therapy
antibiotic resistance
Online Access:https://www.dovepress.com/eradication-rates-for-esomeprazole-and-lansoprazole-based-7-day-non-bi-peer-reviewed-article-IDR

Internet

https://www.dovepress.com/eradication-rates-for-esomeprazole-and-lansoprazole-based-7-day-non-bi-peer-reviewed-article-IDR

Similar Items